Asem Mansour, Chief Executive Officer of King Hussein Cancer Center, Chairperson of Jordan Breast Cancer Program, shared on Facebook:
“Proud to share our latest publication in JCO Global Oncology.
Title: Point-of-Care Manufacturing of Anti-CD19 CAR-T Cells Using CliniMACS Prodigy: Real-World Experience From Jordan
Authors: Khalid Halahleh, Ahmad Abu-Khader, Husam Abu-Jazar, Mohamad Makoseh, Waleed Dana, Rozan Al-Far, Taima’ Qabajah, Mohammad Al-Sharairy, Rula Najjar, Ayat Taqash, Yasmin Al Ra’Ee, Mohammad Al-Rawashdeh, Alaa Abu-Fara, Fatena Ajlouni, Walid Naser, Zaid Abdelrahman, Maysa Al-Hussaini, Imad Treish, Hikmat Abdel-Razeq, Asem Mansour
CAR-T therapy has transformed outcomes for patients with relapsed/refractory lymphoma, but industry-driven manufacturing is complex, costly, and slow, keeping it out of reach for much of the world.
We asked a simple question: can we make it here, ourselves, for our own patients? The answer is yes.
Using an automated, closed system, our team manufactured 11 reproducible CAR-T products in-house, treated our first 8 patients under a phase II trial, and brought the average vein-to-vein time down to just over 15 days, with encouraging responses and no new safety signals.
This is what decentralized, point-of-care cell therapy can look like in a developing country. Deeply grateful to every member of this team who made it possible.”
Other articles about CAR-T therapy on OncoDaily.